Liver health
Liver Health
A change in liver enzyme ALT observed in a 24 week human trial
In a trial of 70 middle aged adults with liver values near the upper limit of normal, ALT was lower in the glucoraphanin group than with placebo after adjustment for baseline values.
- 70 participants
- ALT trial allocation
- 24 weeks
- Trial duration
- 60 mg/day
- GLR dose
ALT · Baseline and Week 24
Median at each time point · U/L
Between-group p = 0.041 after baseline adjustment · 35 assigned to each group
Healthy middle-aged adults · GLR 60 mg/day
Read Satomi · 2022 →View values and units
| Group | Value |
|---|---|
| Placebo · baseline | 35 |
| Placebo · week 24 | 30 |
| GLR · baseline | 36 |
| GLR · week 24 | 29 |
Liver health · research results at a glance
4 studies
Liver enzyme ALT · 24 week controlled trial
| Study and participants | Intake and observation | Findings and context |
|---|---|---|
| Satomi · 2022 70 healthy adults aged 45–65 |
GLR 60mg/day · 24 weeks placebo controlled · 35 assigned to each group | A difference in ALT versus placebo at 24 weeksFinding: Median ALT changed from 36 to 29 U/L in the GLR group and from 35 to 30 U/L with placebo. The baseline adjusted endpoint comparison had p = 0.041. Context: A trial in adults with liver values near the upper limit of normal. AST and glutathione did not differ significantly. |
Men with fatty liver · two month exploratory result
| Study and participants | Intake and observation | Findings and context |
|---|---|---|
| Kikuchi · 2015 Men with fatty liver and elevated liver enzymes |
GLR 30mg/day · sprout extract 2 months · placebo controlled | Median ALT in intake group: 54.0 → 48.5 IU/LFinding: Liver enzymes and a urinary oxidative damage marker fell in the intake group. ALT values are within group medians. Context: The intake group changed from baseline, but the liver enzyme decrease did not differ significantly from placebo. |
Related research · metabolic markers and mechanisms
| Study and participants | Intake and observation | Findings and context |
|---|---|---|
| Dwibedi · 2025 89 adults with prediabetes assigned |
SFN 150μmol/day · 12 weeks extract 35 / placebo 39 participants | Finding: The fatty liver index (FLI) did not differ significantly from placebo. Context: A secondary endpoint in a prediabetes study, using the fatty liver index (FLI) as an indirect measure of liver fat. |
| Yan · 2023 Review of liver disease mechanisms |
Oxidative stress and inflammation pathways of liver injury and fibrosis | Finding: A review of sulforaphane pathways related to oxidative stress, inflammation, and fibrosis. Context: A synthesis of existing cell and animal literature explaining liver related pathways. |
Sources
- Satomi, et al. Front Nutr. 2022;9:1077271.DOI 10.3389/fnut.2022.1077271
- Kikuchi et al. World J Gastroenterol. 2015;21:12457-12467.DOI 10.3748/wjg.v21.i43.12457
- Dwibedi, et al. Nat Microbiol. 2025;10.DOI 10.1038/s41564-025-01932-w
- Yan L, Yan Y. Front Pharmacol. 2023;14:1256029.DOI 10.3389/fphar.2023.1256029